Roughly 1 in 5 men in the United States are diagnosed with prostate cancer during their lifetime. It is the most common malignancy and the second leading cause of death in men in the United States. It possesses a global problem, with recent increases in the incidence outside the western world. If detected early, it is treatable. Surgery, radiation, and pharmaceuticals are used to block testosterone. Most prostate cancers are adenocarcinoma. Gene mutations accumulate and promote abnormal cell division leading to cancer.
When a man is diagnosed with prostate cancer, they face the problem of deciding an initial treatment that could be right for them. The current staging by Gleason does not reflect the understanding of prostate cancer biology nor the implications of this biology for outcomes and management. There needs to be further refinement according to new molecular aberrations that exist within this disease. This refinement may allow us for more precise” personalized” management of prostate adenocarcinoma.
Prostate cancer is the second leading cause of cancer-related death in men in the United States and the third leading cause of cancer-related death in Europe. Recently the treatment of prostate cancer has dramatically changed across the spectrum of the illness. We are now able to identify men that have a higher likelihood of having clinically significant cancer, thus benefit from early detection and immediate treatment. New clinical and biologic biomarkers have shown to determine once localized prostate cancer was diagnosed, which tumors to optimally treat using active surveillance or which tumor needs aggressive treatments.
The widespread use of prostate specific antigen (PSA) yes on fortunately resulted in the increased treatment Of clinically insignificant cancers.
The advent of next-generation sequencing technology has broadened our understanding of the genomic landscape prostate cancer. This technology is genuinely personalized genomic prostate cancer treatment.
The initial therapy for most patients is androgen deprivation therapy which initially works, but later the PSA rises. This therapy is performed by targeting the androgen biosynthesis inhibitors or the androgen receptor activity known as the antiestrogens. At some point, the disease progresses despite androgen deprivation therapy, and the PSA starts to rise. According to the new results of the post-analysis of the randomized phase, 3 TITAN study presented at the genitourinary cancer symposium, “early intensive treatment is important.” Xtandi (Apalutamide) is a selective next-generation androgen receptor inhibitor for the treatment of a man with metastatic and now nonmetastatic castration-resistant prostate cancer.
New molecular genomic testing can improve the outcome and personalize the treatment of prostate cancer. Early progressing patients need aggressive treatment. “We need to identify the molecular targets for these initial signs of progress and figure out these molecular pathways so that we can develop novel agents to target these pathways.
By evaluation of your genetic “biomarkers,” these pathways causing tumor aggressiveness can be blocked and down-regulated. Chemosensitivity testing will evaluate which chemotherapy is most effective in prostate cancer. The natural testing will ascertain which natural substances best utilized. Evaluation of circulating cancer cells both before and after treatment is essential. This treatment can predict your remission prognosis and future outcome.
Provenge (sipuleucel-T) Immunotherapy with cellular immunotherapy is designed to stimulate the patient’s immune system against cancer.
This therapy is dendritic cell-based therapy for prostate cancer and was the first successful demonstration of immunotherapy found. This treatment is relatively nontoxic and provides survival benefits for men with asymptomatic metastasis.
Other cancer vaccines that are now available include autologous whole cancer vaccines, dendritic cell vaccines, and supportive oligonucleotide (SOT). They are all used in combination to provide synergistic effects.
With new molecular personalized testing, we can develop a truly personalized protocol for your prostate cancer. This testing includes low-dose metronomic chemotherapy, androgen deprivation, natural synergistic substances as well as various forms of immunotherapy with cancer vaccines such as Provenge, autologous whole cancer vaccine, dendritic cell vaccine and supportive oligonucleotide (SOT). Other therapies include HIFU, proton therapy, and hyperthermia.
If you would like more information on stage IV prostate cancer, please call less at 480-860-2030.